Main Article Content
Introduction: PHPT was diagnosed on the basis of a study of the content of total calcium and inorganic phosphorus in the blood and in daily urine, ionized calcium in the blood, exercise tests with calcium and sodium chloride, the content of parathyroid hormone (PTH), calcitonin (CT), vitamin D and cyclic 3,5 β-adenosine monophosphate (cAMP) in serum.
Materials and Methods: A total of 2100 children aged 1 to 15 years with patients with urolithiasis were examined, of which 52 (2.5%) children were diagnosed with primary hyperparathyroidism (PHPT). The renal form (RF) of PHPT was 29 (55.7%) and the mixed form (MF) (damage to the kidneys and bones) of PHPT was 23 (44.2%) patients. To detect bone damage, we studied the activity of alkaline phosphatase (ALPL) and X-ray densitometry of the bones of the hand and ultrasound osteometry of the bones.
Results: High rates of alkaline phosphatase (ALPL) and low rates of echoosteometry were observed in children with impaired renal function and had a direct relationship with the number and size of formed stones and osteoporosis of bones.
Discussion: The study of alkaline phosphatase (ALPL) activity and bone echoostometry makes it possible to assess the severity of osteystrophy and accordingly, to differentiate PHPT by forms (renal and mixed) and the severity of the disease.
Ejlsmark-Svensson H, Bislev L, Rolighed L, Sikjaer T, Rejnmark L. Predictors of renal function and calcifications in primary hyperparathyroidism: A nested case-control study. The Journal of Clinical Endocrinology & Metabolism. 2018; 103(9):3574-3583.
Insogna K. Primary hyperparathyroidism. New England Journal of Medicine. 2018;379(11):1050-1059.
Misgar R, Sehgal A, Masoodi S, Wani A, Bashir M, Malik A, et al. A comparison between silent and symptomatic renal stones in primary hyperparathyroidism. Indian Journal of Endocrinology and Metabolism. 2019;23(1):46.
Patel K, Swischuk L, Lee P. Incidental hypercalcemia caused by primary hyperparathyroidism with rapid progression to renal complications in a child. Clinical Pediatrics. 2017;57(1):117-120.
Walker M, Silverberg S. Primary hyperparathyroidism. Nature Reviews Endocrinology. 2017;14(2):115-125.
Gibb F, Muthukrishnan B, Reid L. Critical evaluation of biochemical and imaging diagnostic assessment in primary hyperparathyroidism. Endocrine Abstracts; 2017.
Syed H, Khan A. Primary hyperpara-thyroidism: Diagnosis and management in 2017. Polish Archives of Internal Medicine; 2017.
Marcus R. Laboratory diagnosis of primary hyperparathyroidism. Endocrinology and Metabolism Clinics of North America. 1989;18(3):647-658.
Suzuki S, Fukushima T, Ami H, Asahi S, Onogi H, Nakamura I, et al. Pre- and postoperative bone metabolism of primary hyperparathyroidism. Biomedicine & Pharmacotherapy. 2000;54:90s-96s.
Imanishi Y, Kobayashi K, Kawata T, Inaba M, Nishizawa Y. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases. Therapeutic Apheresis and Dialysis. 2007;11(s1):S32-S37.
Moosgaard B, Christensen S, Vestergaard P, Heickendorff L, Christiansen P, Mosekilde L. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clinical Endocrino-logy. 2008;68(5):707-715.
Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. Journal of Bone and Mineral Research. 2001;16(1):113-119.
Kollars J, Zarroug A, van Heerden J, Lteif A, Stavlo P, Suarez L, et al. Primary hyperparathyroidism in pediatric Patients. Pediatrics. 2005;115(4):974-980.
Yaghoubi F, Yarmohamadi M. Recurrent nephrolithiasis leading to renal failure: A neglected primary hyperparathyroidism. Nephro-Urology Monthly. 2018;10(2).